Table of Content

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary research
1.3.5 Sample size for the study on Intravenous Iron Drugs Market
1.3.6 List of Secondary Data Sources
1.4 Information or Data Analysis
1.5 Market Formulation and Validation
1.6 Market Model
1.6.1 Market study, by company market share
1.6.2 Regional analysis
1.7 Research Assumptions
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot, 2022
2.2 Segment Snapshot
2.3 Competitive Snapshot
Chapter 3 Intravenous Iron Drugs Market – Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.1.2 Related/Ancillary market outlook
3.1.2.1 Inflammatory Bowel Disease Treatment Market
3.1.2.2 Anemia Treatment Market
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Increasing prevalence of target diseases
3.2.1.2 Increasing iron deficiency anemia cases
3.2.1.3 Advantages of intravenous iron drugs
3.2.2 Market restraint analysis
3.2.2.1 Adverse effects associated with iron drugs
3.2.2.2 Increasing approvals of oral iron drugs
3.3 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.4 Industry Analysis – Porter’s
3.5 COVID-19 Impact Analysis
Chapter 4 Intravenous Iron Drugs Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
4.1 Intravenous Iron Drugs Market: Product Movement Analysis
4.2 Intravenous Iron Drugs Market Estimates & Forecast, by Product (USD Million)
4.2.1 Iron Dextran
4.2.2 Iron Sucrose
4.2.3 Ferric Carboxymaltose
4.2.4 Others
Chapter 5 Intravenous Iron Drugs Market – Segment Analysis, by Application, 2018 – 2030 (USD Million)
5.1 Intravenous Iron Drugs Market: Application Movement Analysis
5.2 Intravenous Iron Drugs Market Estimates & Forecast, by Application (USD Million)
5.2.1 Chronic Kidney Disease
5.2.2 Inflammatory Bowel Disease
5.2.3 Cancer
5.2.4 Other Diseases
Chapter 6 Intravenous Iron Drugs Market: Regional Estimates and Trend Analysis
6.1 Intravenous Iron Drugs Market: Regional Outlook
6.2 North America
6.2.1 North America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 U.S. Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.2.2.3 Target Disease Prevalence
6.2.2.4 Market & Competitive Scenario
6.2.2.5 Regulatory Framework
6.2.2.6 Reimbursement Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Canada Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.2.3.3 Target Disease Prevalence
6.2.3.4 Market & Competitive Scenario
6.2.3.5 Regulatory Framework
6.2.3.6 Reimbursement Scenario
6.3 Europe
6.3.1 Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 UK Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.2.3 Target Disease Prevalence
6.3.2.4 Market & Competitive Scenario
6.3.2.5 Regulatory Framework
6.3.2.6 Reimbursement Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Germany Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.3.3 Target Disease Prevalence
6.3.3.4 Market & Competitive Scenario
6.3.3.5 Regulatory Framework
6.3.3.6 Reimbursement Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 France Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.4.3 Target Disease Prevalence
6.3.4.4 Market & Competitive Scenario
6.3.4.5 Regulatory Framework
6.3.4.6 Reimbursement Scenario
6.3.5 Italy
6.3.5.1 Key Country Dynamics
6.3.5.2 Italy Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.5.3 Target Disease Prevalence
6.3.5.4 Market & Competitive Scenario
6.3.5.5 Regulatory Framework
6.3.5.6 Reimbursement Scenario
6.3.6 Spain
6.3.6.1 Key Country Dynamics
6.3.6.2 Spain Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.6.3 Target Disease Prevalence
6.3.6.4 Market & Competitive Scenario
6.3.6.5 Regulatory Framework
6.3.6.6 Reimbursement Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Denmark Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.7.3 Target Disease Prevalence
6.3.7.4 Market & Competitive Scenario
6.3.7.5 Regulatory Framework
6.3.7.6 Reimbursement Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Sweden Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.8.3 Target Disease Prevalence
6.3.8.4 Market & Competitive Scenario
6.3.8.5 Regulatory Framework
6.3.8.6 Reimbursement Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Norway Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.9.3 Target Disease Prevalence
6.3.9.4 Market & Competitive Scenario
6.3.9.5 Regulatory Framework
6.3.9.6 Reimbursement Scenario
6.3.9.7 Rest of Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Japan Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2.3 Target Disease Prevalence
6.4.2.4 Market & Competitive Scenario
6.4.2.5 Regulatory Framework
6.4.2.6 Reimbursement Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 China Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.3.3 Target Disease Prevalence
6.4.3.4 Market & Competitive Scenario
6.4.3.5 Regulatory Framework
6.4.3.6 Reimbursement Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 India Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.4.3 Target Disease Prevalence
6.4.4.4 Market & Competitive Scenario
6.4.4.5 Regulatory Framework
6.4.4.6 Reimbursement Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Australia Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.5.3 Target Disease Prevalence
6.4.5.4 Market & Competitive Scenario
6.4.5.5 Regulatory Framework & Reimbursement Scenario
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.6.3 Target Disease Prevalence
6.4.6.4 Market & Competitive Scenario
6.4.6.5 Regulatory Framework
6.4.6.6 Reimbursement Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.7.3 Target Disease Prevalence
6.4.7.4 Market & Competitive Scenario
6.4.7.5 Regulatory Framework/Reimbursement Scenario
6.4.7.6 Rest of Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Brazil Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2.3 Target Disease Prevalence
6.5.2.4 Market & Competitive Scenario
6.5.2.5 Regulatory Framework
6.5.2.6 Reimbursement Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.3.3 Target Disease Prevalence
6.5.3.4 Market & Competitive Scenario
6.5.3.5 Regulatory Framework
6.5.3.6 Reimbursement Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Argentina Intravenous Iron Drugs Market Estimates and forecasts, 2018 – 2030 (USD Million)
6.5.4.3 Target Disease Prevalence
6.5.4.4 Market & Competitive Scenario
6.5.4.5 Regulatory Framework
6.5.4.6 Reimbursement Scenario
6.5.4.7 Rest of Latin America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.6 MEA
6.6.1 MEA Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2.3 Target Disease Prevalence
6.6.2.4 Market & Competitive Scenario
6.6.2.5 Regulatory Framework
6.6.2.6 Reimbursement Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.3.3 Target Disease Prevalence
6.6.3.4 Market & Competitive Scenario
6.6.3.5 Regulatory Framework
6.6.3.6 Reimbursement Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.4.3 Target Disease Prevalence
6.6.4.4 Market & Competitive Scenario
6.6.4.5 Regulatory Framework
6.6.4.6 Reimbursement Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.5.3 Target Disease Prevalence
6.6.5.4 Market & Competitive Scenario
6.6.5.5 Regulatory Framework
6.6.5.6 Reimbursement Scenario
6.6.5.7 Rest of MEA Intravenous Iron Drugs Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Allergan, Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic initiatives
7.4.2 AMAG Pharmaceuticals. Inc.
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic initiatives
7.4.3 Daiichi Sankyo Company, Ltd.
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic initiatives
7.4.4 Sanofi
7.4.4.1 Company overview
7.4.4.2 Financial performance
7.4.4.3 Product benchmarking
7.4.4.4 Strategic initiatives
7.4.5 Fresenius Medical Care AG & Co.
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic initiatives
7.4.6 Vifor Pharma Management Ltd.
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic initiatives
7.4.7 Pharmacosmos A/S
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic initiatives
7.4.8 Shield Therapeutics Plc
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic initiatives
7.4.9 American Regent. Inc.
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic initiatives